cxcr4 peptide antagonist CXCR4 antagonist - custom-peptide-synthesis-company-address CXCR4 peptide antagonist Exploring the Potential of CXCR4 Peptide Antagonists in Therapeutic Applications

ghk-cu-safety-human-studies The *CXCR4 peptide antagonist* landscape is rapidly evolving, offering promising avenues for treating a range of diseases, particularly cancers. Research highlights the critical role of the CXC chemokine receptor 4 (CXCR4) and its ligand CXCL12 in various biological processes, including cell migration, proliferation, and inflammation作者：Z Sahin·2025·被引用次数：3—TheCXCR4 antagonistPlerixafor (AMD3100,1) was shown to mobilize these cells and currently is approved as a treatment for HSPC mobilization in combination with .... Aberrant expression of these molecules is frequently observed in numerous pathological conditions, making them attractive therapeutic targets.

CXCR4 peptide antagonists are a class of molecules designed to block the activity of the CXCR4 receptor. This blockage can disrupt signaling pathways that promote disease progression. For instance, studies have demonstrated that CXCR4 antagonists can inhibit tumor growth and metastasisAn inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration,CXCR4 inhibitor LY2510924binds .... The CXCR4 peptide antagonist LY2510924, explored in a phase I trial, showed promise in evaluating its safety and tolerability. This specific *peptide antagonist* exhibits potent and selective CXCR4 antagonistic activity, impacting various cancer types, including renal cell carcinoma, lung cancer, colon cancer, and breast cancer.

Beyond LY2510924, other agents are making significant strides作者：O Zirafi·2015·被引用次数：120—EPI-X4 forms an unusual lasso-like structure andantagonizes CXCL12-induced tumor cell migration, mobilizes stem cells, and suppresses inflammatory responses .... CTCE-9908, a CXCR4 peptide antagonist, has shown a notable 45% inhibition of primary tumor growth in studies, indicating its potential in slowing tumor progression [1]. Another important player in this field is Plerixafor, also known as AMD3100.Improving the inhibitory effect of CXCR4 peptide antagonist ... While primarily a *small molecule* CXCR4 antagonist, its ability to mobilize stem cells for transplantation is well-establishedCXCR4 peptide antagonist inhibits primary breast tumor .... AMD3100, an antagonist of the chemokine receptor CXCR4, has been approved for a specific therapeutic use and is being investigated for its role in preventing the accumulation of leukemic cells in the bone marrow, thereby enhancing treatment efficacy [2].Small molecule and peptide CXCR4 antagonists. A patent ... The development of N-Terminally Modified Variants of the CXCR4 receptors is also an active area of research, aiming to refine existing antagonist profiles.

Furthermore, the discovery of endogenous CXCR4 antagonists, such as EPI-X4, has expanded the understanding of natural regulatory mechanisms. EPI-X4 possesses a unique lasso-like structure and demonstrates the ability to antagonize CXCL12-induced tumor cell migration, mobilize stem cells, and suppress inflammatory responses [3]. The development of modified peptides, like the E5 peptide antagonist, is also yielding specific CXCR4 binders with potential therapeutic benefits [4].作者：H Guo·2017·被引用次数：39—Peptide LY2510924 is a potent and selective CXCR4 antagonistfor inhibiting renal cell carcinoma, lung, colon cancer and breast cancer that ...

The application of CXCR4 peptide antagonists extends to diagnostic imaging as well. Researchers have developed labeled derivatives, such as a CXCR4 peptide antagonist labeled with copper-64, enabling Positron Emission Tomography (PET) imaging. This innovation allows for better visualization and characterization of CXCR4 expression in vivo [5].作者：M Harms·2023·被引用次数：11—Currently, the only FDA-approved CXCR4 antagonist is the small moleculeAMD3100, which is used for peripheral blood stem cell transplantation ...

The mechanism of action for these peptide antagonists involves binding to the CXCR4 receptor, thereby preventing its interaction with CXCL12作者：O Zirafi·2015·被引用次数：120—EPI-X4 forms an unusual lasso-like structure andantagonizes CXCL12-induced tumor cell migration, mobilizes stem cells, and suppresses inflammatory responses .... This interaction is crucial for processes like CXCL12-induced tumor cell migration. By disrupting this axis, CXCR4 peptide antagonists can limit cancer cell spread and growth. The CXCR4 receptor itself is a G protein-coupled receptor that plays a pivotal role in the immune response and cell trafficking. Understanding its intricate signaling pathways is key to developing effective therapeutic strategies.In this study we developed a derivative of theCXCR4 peptide antagonist, T140-2D, that can be labeled easily with the PET isotope copper-64, and thereby enable ...

Ongoing research is focused on optimizing the efficacy and safety profiles of these compounds. This includes exploring biased antagonism of CXCR4 to avoid antagonist tolerance [6], a mechanism that could lead to more sustained therapeutic effects.Definition of CXCR4 peptide antagonist LY2510924 The development of novel peptide antagonist molecules, alongside advancements in understanding the intricate roles of the CXCR4 receptor in various disease states, signifies a promising future for targeted therapiesDevelopment of N-Terminally Modified Variants of the CXCR4 ....

---

References:

[1] Hassan, S., et al.Development of N-Terminally Modified Variants of the CXCR4 ... (Year of Publication).作者：B Hitchinson·2018·被引用次数：57—AMD3100, an antagonist of the chemokine receptor CXCR4, prevents the accumulation of leukemic cells in the bone marrow, which promotes the efficacy of ... CXCR4 peptide antagonist inhibits primary breast tumor.Small molecule and peptide CXCR4 antagonists. A patent ..... (Note: Specific publication year and journal details would be needed for a complete citation).作者：B Hitchinson·2018·被引用次数：57—AMD3100, an antagonist of the chemokine receptor CXCR4, prevents the accumulation of leukemic cells in the bone marrow, which promotes the efficacy of ...

[2] Hitchinson, BAn inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration,CXCR4 inhibitor LY2510924binds ...., et al. (Year of Publication). Biased antagonism of CXCR4 avoids antagonist toleranceA Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist .... (Note: Specific publication year and journal details would be needed for a complete citation).

[3] Zirafi, O.In this study we developed a derivative of theCXCR4 peptide antagonist, T140-2D, that can be labeled easily with the PET isotope copper-64, and thereby enable ..., et al. (Year of Publication). Discovery and Characterization of an Endogenous CXCR4In this study we developed a derivative of theCXCR4 peptide antagonist, T140-2D, that can be labeled easily with the PET isotope copper-64, and thereby enable ......Development of N-Terminally Modified Variants of the CXCR4 ... (Note: Specific publication year and journal details would be needed for a complete citation).

[4] Liu, C.Definition of CXCR4 peptide antagonist LY2510924, et al. (Year of Publication). Improving the inhibitory effect of CXCR4 peptide antagonist...作者：Z Sahin·2025·被引用次数：3—TheCXCR4 antagonistPlerixafor (AMD3100,1) was shown to mobilize these cells and currently is approved as a treatment for HSPC mobilization in combination with ... (Note: Specific publication year and journal details would be needed for a complete citation).Definition of CXCR4 peptide antagonist LY2510924

[5] (Details regarding PET imaging with copper-64 labeled peptide would require a specific publication citation).

[6] Hitchinson, B., et al. (Year of Publication). Biased antagonism of CXCR4 avoids antagonist tolerance. (Note: Specific publication year and journal details would be needed for a complete citation)作者：MD Galsky·2014·被引用次数：133—This article reports the results of a phase I study designed to evaluate the safety and tolerability of the CXC motif receptor 4 (CXCR4) inhibitor LY2510924 in ....